IMPORTANT INFORMATION FOR PRIVATE INVESTORS

Our investments place your capital at risk. We do not provide investment, tax or legal advice and we recommend you seek professional advice if you are considering investing with us. You may lose part or all of the amount you invest with us. We invest in unquoted shares in small companies. The value of these shares can be volatile, and the shares are often difficult to sell. The tax reliefs associated with our investments depend on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results. Our forecasts and performance targets cannot accurately predict how investments will perform.

ACCEPT DECLINE
Change Visitor Type

Portfolio

Oxford BioTherapeutics

Oxford BioTherapeutics is an oncology drug discovery business. By exploiting its proprietary database of human cell-surface proteins, it creates and develops novel targeted oncology therapeutics, with a focus on Antibody Drug Conjugates and Immune Oncology treatments.

26

  • Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi

    Read more

  • Oncology research: New opportunities for Menarini and OBT

    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more

  • Oxford BioTherapeutics receives $10 million capital term loan from Silicon Valley Bank

    Read more

  • $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics

    Read more

  • Oxford BioTherapeutics Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance

    Read more